Sign In
Buy EIGR
$1.73
+0 (+0%)
At Close: Aug 27, 2024
Is Eiger BioPharmaceuticals (EIGR) Stock a Solid Choice Right Now?
12:57pm, Friday, 15'th May 2020
Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda
12:00pm, Thursday, 30'th Apr 2020
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the first patients h
Eiger Biopharmaceuticals (EIGR) Gets a Buy Rating from Wedbush
01:25pm, Tuesday, 28'th Apr 2020
Wedbush analyst Liana Moussatos maintained a Buy rating on Eiger Biopharmaceuticals (EIGR – Research Report) today and set a price
Bank of New York Mellon Corp Purchases 1,926 Shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR)
08:18am, Saturday, 25'th Apr 2020
Bank of New York Mellon Corp grew its position in shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 2.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities
Will Eiger BioPharmaceuticals Continue to Surge Higher?
02:05pm, Wednesday, 22'nd Apr 2020
As of late, it has definitely been a great time to be an investor Eiger BioPharmaceuticals
Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays
10:08pm, Thursday, 09'th Apr 2020
Sean McCarthy, president and CEO of CytomX Therapeutics Inc.
14,375 Shares in Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) Bought by Connor Clark & Lunn Investment Management Ltd.
08:56am, Thursday, 09'th Apr 2020
Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) during the fourth quarter, according to its most recent disclosure with the
-$0.85 EPS Expected for Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) This Quarter
09:48am, Monday, 06'th Apr 2020
Equities analysts expect that Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) will announce earnings per share (EPS) of ($0.85) for the current quarter, Zacks Investment Research reports. Zero analysts hav
Reviewing Eiger Biopharmaceuticals (NASDAQ:EIGR) and Halozyme Therapeutics (NASDAQ:HALO)
06:10am, Saturday, 04'th Apr 2020
Eiger Biopharmaceuticals (NASDAQ:EIGR) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength
Wedbush Thinks Eiger Biopharmaceuticals’ Stock is Going to Recover
10:21am, Friday, 03'rd Apr 2020
Wedbush analyst
Liana Moussatos
maintained a
Buy
rating on Eiger Biopharmaceuticals (
EIGR
–
Research Report
) today and set a price target of
$33.00
. The company’s shares closed last Thursday at
Here's a roundup of top developments in the biotech space over the last 24 hours.On a day when the three major averages shed over 4% in reaction to bleak forecasts concerning the COVID-19 pandemic's
Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic
08:05pm, Wednesday, 01'st Apr 2020
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today provided an update on the impact o
Eiger Biopharmaceuticals (EIGR) Receives a Buy from Wedbush
07:14pm, Tuesday, 24'th Mar 2020
In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Eiger Biopharmaceuticals (EIGR – Research Report),
Eiger Completes NDA Submission of Progeria Drug Lonafarnib
02:25pm, Tuesday, 24'th Mar 2020
Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it has completed su
